🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guadalajara
Clinical trial register · Mexico

Clinical Trials in Guadalajara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1580 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
1580
Studies in scope
all four open statuses
714
Recruiting now
open to new participants
249
Lead sponsors
across recruiting studies
Top sites
Mexico City 41 Guadalajara 24 Monterrey 18 Culiacán 11 México 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company40 AstraZeneca35 Merck Sharp & Dohme LLC30 Hoffmann-La Roche24 Bristol-Myers Squibb18 Clear sponsor filter
Site location
Mexico City41 Guadalajara24 Monterrey18 Culiacán11 México8
All 41 locations
Target enrolment
to

Trials with a site in Guadalajara

24 of 1580 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07598396Lupus, Systemic Lupus Erythematosus, Lupus Nephritis
DrugMosunetuzumab
Hoffmann-La Roche
Phase 2
30
Torreón, Mexicali, Guadalajara, México, Culiacán
2026-05-25
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
DrugsInavolisib·Ribociclib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
Distrito Federal, Oaxaca City, Guadalajara
2026-04-07
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Col Saucito, Guadalajara, México, Delegacion Cuauhtemoc, Cuernavaca, San Pedro Garza García, Ciudad Madero
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Col Saucito, Guadalajara, Delegacion Cuauhtemoc, México, Cuernavaca, San Pedro Garza García, Ciudad Madero
2026-03-16
Recruiting
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT07368998Breast Cancer
DrugsInavolisib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
Guadalajara, Queretaro Qro, Mexico City
2026-02-18
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Guadalajara, Mexico City
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Distrito Federal, MexicoCiudad de México, Monterrey, Ciudad de Huajuapan de León, Oaxaca City, Chihuahua City, D.F., Guadalajara
2025-04-09
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Guadalajara, Mexico, Mérida
2025-03-17
Active, closed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
NCT07667322Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 1
75
Guadalajara, Mexico City
2024-12-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Guadalajara, Monterrey
2024-09-17
Active, closed
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986Systemic Lupus Erythematosus
DrugTocilizumab
Hoffmann-La Roche
Phase 1
70
Guadalajara, Mexico City
2023-12-18
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Guadalajara, Mexico City, Monterrey, Oaxaca City, Queréaro
2023-12-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Guadalajara, Mexico City, Monterrey
2023-09-08
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
DrugAstegolimab
Hoffmann-La Roche
Phase 3
2,000
Guadalajara, Santa Cecilia, Monterrey
2023-06-28
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsBupropion·Omeprazole·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
Guadalajara, Mexico City, Distrito Federal, Morelia
2023-06-07
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204Non-Small Cell Lung Cancer
DrugsEntrectinib·Alectinib·Durvalumab
Hoffmann-La Roche
Phase 3
68
Guadalajara
2022-11-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsPhesgo·Giredestrant·Docetaxel·Paclitaxel
Hoffmann-La Roche
Phase 3
922
La Paz, Guadalajara, D.F., Mexico City, Monterrey, Querétaro City, San Luis Potosí City, Chihuahua City
2022-07-18
Active, closed
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05123703Relapsing-remitting Multiple Sclerosis
DrugsFingolimod·Ocrelizumab
Hoffmann-La Roche
Phase 3
188
Guadalajara, Mexico City, Morelia, Culiacán, Veracruz
2022-05-19
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
NCT05039619Lupus Nephritis
DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Mycophenolate Mofetil·Methylprednisolone
Hoffmann-La Roche
Phase 2
40
Guadalajara, Mexico City, Monterrey
2022-05-12
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Guadalajara, Mexico City, Tlalnepantla, Monterrey, Culiacán, Chihuahua City, México
2022-05-03
Active, closed
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807Carcinoma, Non-Small-Cell Lung
DrugsEntrectinib·Crizotinib
Hoffmann-La Roche
Phase 3
217
Guadalajara, Mexico City
2021-09-30
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Mexicali, León, Guadalajara, Mexico City, Monterrey, Oaxaca City, Querétaro City, Culiacán
2021-08-27
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
769
Guadalajara, Mexico City, San Luis Potosí City, México
2020-12-03
Active, closed
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
DrugTobemstomig
Hoffmann-La Roche
Phase 1/2
170
Guadalajara, Mexico City, Querétaro City
2019-11-11
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-mexico/city/guadalajara

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,580 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Guadalajara that also match the filters currently applied.

How many clinical trials are recruiting in Guadalajara?

11 of the 24 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guadalajara), 24 studies
PhaseStudiesRecruitingShare
Phase 317770.8%
Phase 24416.7%
Phase 1208.3%
Phase 1/2104.2%

Most active sponsors

Lead sponsors with the most studies (Guadalajara)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche2411
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.